{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:40:33Z","timestamp":1793886033321,"version":"4.8.0"},"reference-count":252,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12\/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced by macrophages and dendritic cells, in response to exogenous or endogenous signals, and drives the differentiation and activation of T helper 17 (Th17) cells with subsequent production of IL-17A, IL-17F, IL-6, IL-22, and tumor necrosis factor \u03b1 (TNF-\u03b1). Although IL-23 plays a pivotal role in the protective immune response to bacterial and fungal infections, its dysregulation has been shown to exacerbate chronic immune-mediated inflammation. Well-established experimental data support the concept that IL-23\/IL-17 axis activation contributes to the development of several inflammatory diseases, such as PsA, Psoriasis, Psoriatic Arthritis; AS, Ankylosing Spondylitis; IBD, Inflammatory Bowel Disease; RA, Rheumatoid Arthritis; SS, Sjogren Syndrome; MS, Multiple Sclerosis. As a result, emerging clinical studies have focused on the blockade of this pathogenic axis as a promising therapeutic target in several autoimmune disorders; nevertheless, a greater understanding of its contribution still requires further investigation. This review aims to elucidate the most recent studies and literature data on the pathogenetic role of IL-23 and Th17 cells in inflammatory rheumatic diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2021.637829","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T23:20:53Z","timestamp":1613949653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":347,"title":["Role of the IL-23\/IL-17 Pathway in Rheumatic Diseases: An Overview"],"prefix":"10.3389","volume":"12","author":[{"given":"Claudia","family":"Schinocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"La Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.4049\/jimmunol.176.2.1098","article-title":"IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12","volume":"176","author":"Kleinschek","year":"2006","journal-title":"J Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity."},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.it.2005.10.003","article-title":"Understanding the IL-23\/IL-17 immune pathway","volume":"27","author":"McKenzie","year":"2006","journal-title":"Trends Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.molimm.2009.01.004","article-title":"Synergism between tumor necrosis factor a and interleukin-17 to induce IL-23 p19 expression in fibroblast- like synoviocytes","volume":"46","author":"Goldberg","year":"2009","journal-title":"Mol Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/ard.2007.082081","article-title":"Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis","volume":"68","author":"Brentano","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2567.2008.03017.x","article-title":"Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens","volume":"126","author":"Curtis","year":"2009","journal-title":"Immunology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.4049\/jimmunol.170.11.5438","article-title":"IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14\/p40 transgenic mice: evidence for enhanced cutaneous immunity","volume":"170","author":"Kopp","year":"2003","journal-title":"J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.4049\/jimmunol.168.11.5448","article-title":"IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells","volume":"168","author":"Belladonna","year":"2002","journal-title":"J Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2567.2005.02118.x","article-title":"Analysis of the activation profile of dendritic cells derived from the bone marrow of interleukin-12\/interleukin-23-deficient mice","volume":"114","author":"Bastos","year":"2005","journal-title":"Immunology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1600-6143.2006.01651.x","article-title":"The interleukin-12 family: new players in transplantation immunity?","volume":"7","author":"Goriely","year":"2007","journal-title":"Am J Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nri2225","article-title":"How microorganisms tip the balance between interleukin-12 family members","volume":"8","author":"Goriely","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4049\/jimmunol.156.1.5","article-title":"Mice with a disrupted IFN-c gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)","volume":"156","author":"Ferber","year":"1996","journal-title":"J Immunol."},{"key":"B16","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.4049\/jimmunol.158.11.5507","article-title":"Accelerated collagen-induced arthritis in IFN-c receptor-deficient mice","volume":"158","author":"Vermeire","year":"1997","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.4049\/jimmunol.158.11.5501","article-title":"High susceptibility to collagen induced arthritis in mice lacking IFN-c receptors","volume":"158","author":"Manoury-Schwartz","year":"1997","journal-title":"J Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-c: an overview of signals,mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1365-2567.2010.03275.x","article-title":"Dendritic cell differentiation with prostaglandin E results in selective attenuation of the extracellular signal-related kinase pathway and decreased interleukin-23 production","volume":"131","author":"Hayashi","year":"2010","journal-title":"Immunology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1182\/blood-2008-05-155408","article-title":"Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion","volume":"112","author":"Chizzolini","year":"2008","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","article-title":"IL-12 and IL-23: master regulators of innate and adaptive immunity","volume":"202","author":"Langrish","year":"2004","journal-title":"Immunol Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.4049\/jimmunol.179.12.8098","article-title":"IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis","volume":"179","author":"Kreymborg","year":"2007","journal-title":"J. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.4049\/jimmunol.0901588","article-title":"IL-23 is required for protection against systemic infection with Listeria monocytogenes","volume":"183","author":"Meeks","year":"2009","journal-title":"J. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.4049\/jimmunol.0902796","article-title":"IL-23 receptor regulates unconventional IL-17-producing T cells that control bacterial infections","volume":"184","author":"Riol-Blanco","year":"2010","journal-title":"J. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/eji.200940157","article-title":"Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis","volume":"40","author":"Wakita","year":"2010","journal-title":"Eur J Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity."},{"key":"B30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.immuni.2010.08.013","article-title":"Gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism","volume":"33","author":"Petermann","year":"2010","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 a novel cytokine receptor subunit, IL-23RJ","volume":"168","author":"Parham","year":"2002","journal-title":"Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.4049\/jimmunol.171.9.4485","article-title":"Role of IL-12 receptor beta 1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis","volume":"171","author":"Zhang","year":"2003","journal-title":"J. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1365-2567.2008.02985.x","article-title":"Induction of lymphotoxin-a by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70","volume":"127","author":"Pahan","year":"2009","journal-title":"Immunology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1600-065X.2008.00715.x","article-title":"Reconciling id, ego, and superego within interleukin-23","volume":"226","author":"Tato","year":"2008","journal-title":"Immunol Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev.immunol.22.012703.104758","article-title":"Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation","volume":"25","author":"Kastelein","year":"2007","journal-title":"Annu Rev Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1074\/jbc.272.9.6073","article-title":"Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases","volume":"272","author":"Zou","year":"1997","journal-title":"J Biol Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.4049\/jimmunol.172.5.2827","article-title":"Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice","volume":"172","author":"Ghilardi","year":"2004","journal-title":"J Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.coi.2006.09.008","article-title":"The IL-23\/Th(17) axis: therapeutic targets for autoimmune inflammation","volume":"18","author":"Kikly","year":"2006","journal-title":"Curr Opin Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ni.1698","article-title":"Interleukin 23 receptor is essential for terminal differentiation of effector T helper type 17 cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu Rev Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine."},{"key":"B43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1006\/cyto.1998.0433","article-title":"Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway","volume":"11","author":"Shin","year":"1999","journal-title":"Cytokine."},{"key":"B44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.coi.2008.03.006","article-title":"gammadelta T cells: an important source of IL-17","volume":"20","author":"Roark","year":"2008","journal-title":"Curr Opin Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.4049\/jimmunol.180.8.5167","article-title":"Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion","volume":"180","author":"Rachitskaya","year":"2008","journal-title":"J Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.4049\/jimmunol.0900732","article-title":"Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells","volume":"182","author":"Awasthi","year":"2009","journal-title":"J. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature05969","article-title":"Essential autocrine regulation by IL-21 in the generation of inflammatory T cells","volume":"448","author":"Nurieva","year":"2007","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/art.22866","article-title":"Distinct regulation of interleukin-17 in human T helper lymphocytes","volume":"56","author":"Chen","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B55","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbrc.2009.05.140","article-title":"TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23","volume":"386","author":"Morishima","year":"2009","journal-title":"Biochem Biophys Res Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature05970","article-title":"IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells","volume":"448","author":"Korn","year":"2007","journal-title":"Nature."},{"key":"B59","doi-asserted-by":"publisher","first-page":"20846","DOI":"10.1073\/pnas.0809077106","article-title":"IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype","volume":"105","author":"Huber","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B60","doi-asserted-by":"publisher","first-page":"34605","DOI":"10.1074\/jbc.M705100200","article-title":"IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner","volume":"282","author":"Wei","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.smim.2007.10.011","article-title":"Transcriptional regulation of Th17 cell differentiation","volume":"19","author":"Ivanov","year":"2007","journal-title":"Semin Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ni.1610","article-title":"The differentiation of human T(H)- 17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat","volume":"9","author":"Manel","year":"2008","journal-title":"Nat Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1084\/jem.20061675","article-title":"Interleukin 25 promotes the initiation of proallergic type 2 responses","volume":"204","author":"Angkasekwinai","year":"2007","journal-title":"J Exp Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ni1375","article-title":"Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells","volume":"7","author":"Batten","year":"2006","journal-title":"Nat Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/ni1376","article-title":"Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system","volume":"7","author":"Stumhofer","year":"2006","journal-title":"Nat Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.immuni.2015.12.003","article-title":"Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions","volume":"43","author":"Patel","year":"2015","journal-title":"Immunity."},{"key":"B69","doi-asserted-by":"publisher","first-page":"27467","DOI":"10.1074\/jbc.273.42.27467","article-title":"Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB","volume":"273","author":"Shalom-Barak","year":"1998","journal-title":"J Biol Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40259-014-0098-x","article-title":"The role of interleukin-17A in psoriatic disease","volume":"28","author":"Adami","year":"2014","journal-title":"BioDrugs."},{"key":"B71","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.4049\/jimmunol.162.4.2347","article-title":"Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways","volume":"162","author":"Laan","year":"1999","journal-title":"J Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.4049\/jimmunol.170.9.4432","article-title":"Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection","volume":"170","author":"Happel","year":"2003","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1084\/jem.20050193","article-title":"Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae","volume":"202","author":"Happel","year":"2005","journal-title":"J Exp Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ni.3211","article-title":"T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26","volume":"16","author":"Meller","year":"2015","journal-title":"Nat Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4049\/jimmunol.1500909","article-title":"IL-17-mediated immunity to the opportunistic fungal pathogen candida albicans","volume":"195","author":"Conti","year":"2015","journal-title":"J Immunol."},{"key":"B76","first-page":"250","article-title":"Pneumocystis pneumonia\u2014Los Angeles","volume":"30","year":"1981","journal-title":"MMWR"},{"key":"B77","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0733-8635(18)30717-4","article-title":"Oral mucosal manifestations of AIDS","volume":"5","author":"Greenspan","year":"1987","journal-title":"Dermatol. Clin."},{"key":"B78","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/ni1467","article-title":"Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-\u03b3 or IL-10 and are regulated by IL-1\u03b2","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature."},{"key":"B80","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1086\/422329","article-title":"Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice","volume":"190","author":"Huang","year":"2004","journal-title":"J Infect Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J Exp Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1128\/IAI.01389-13","article-title":"Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis","volume":"82","author":"Ferreira","year":"2014","journal-title":"Infect Immun."},{"key":"B83","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4049\/jimmunol.169.2.642","article-title":"Cutting edge: IL\u221217 D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis","volume":"169","author":"Starnes","year":"2002","journal-title":"J Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.molimm.2007.04.027","article-title":"IL-17 attenuates the anti-apoptotic effects of GM-CSF in human neutrophils","volume":"45","author":"Dragon","year":"2008","journal-title":"Mol Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2002-05-1461","article-title":"Interleukin-17 promotes angiogenesis and tumor growth","volume":"101","author":"Numasaki","year":"2003","journal-title":"Blood."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/1529-0131(200005)43:5&lt;1134::AID-ANR24&gt;3.0.CO;2-#","article-title":"Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte\/macrophages: a possible role in rheumatoid arthritis","volume":"43","author":"Jovanovic","year":"2000","journal-title":"Arthritis Rheum."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1074\/jbc.M308809200","article-title":"Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT\/enhancer-binding protein family members","volume":"279","author":"Ruddy","year":"2004","journal-title":"J Biol Chem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest."},{"key":"B90","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/135245859900500206","article-title":"Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis","volume":"5","author":"Matusevicius","year":"1999","journal-title":"Mult Scler."},{"key":"B91","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm0502-500","article-title":"Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis","volume":"8","author":"Lock","year":"2002","journal-title":"Nat Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing Spondylitis and Axial Spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"New Engl J Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B95","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"Van der Heijde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/art.1780401015","article-title":"Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment","volume":"40","author":"Brown","year":"1997","journal-title":"Arthritis Rheum."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3892\/mmr.2017.6248","article-title":"Role of HLA-B27 in the pathogenesis of ankylosing spondylitis","volume":"15","author":"Chen","year":"2017","journal-title":"Mol Med Rep."},{"key":"B99","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of ankylosing spondylitis-insights into pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2013.07.013","article-title":"HLA-B27 misfolding and ankylosing spondylitis","volume":"57","author":"Colbert","year":"2014","journal-title":"Mol Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2018.02668","article-title":"The early phases of ankylosing spondylitis: emerging insights from clinical and basic science","volume":"9","author":"Watad","year":"2018","journal-title":"Front Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/art.24763","article-title":"HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats","volume":"60","author":"DeLay","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.4049\/jimmunol.175.4.2438","article-title":"HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response","volume":"175","author":"Turner","year":"2005","journal-title":"J Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1002\/art.21395","article-title":"Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis","volume":"54","author":"Chan","year":"2005","journal-title":"Arthritis and Rhum."},{"key":"B105","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci","volume":"45","year":"2013","journal-title":"Nat Genet."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","year":"2007","journal-title":"Nat Genet."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/ni860","article-title":"The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8\u20139 residues","volume":"3","author":"York","year":"2002","journal-title":"Nat Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1002\/art.38809","article-title":"Endoplasmic reticulum degradation\u2013enhancing \u03b1-mannosidase\u2013like protein 1 targets misfolded hla\u2013b27 dimers for endoplasmic reticulum\u2013associated degradation","volume":"66","author":"Guiliano","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"7146","DOI":"10.1038\/ncomms8146","article-title":"Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1","volume":"6","author":"Cortes","year":"2015","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/art.23389","article-title":"Association of interleukin-23 receptor variants with ankylosing spondylitis","volume":"58","author":"Rahman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B111","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nature Genetics."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PLoS ONE."},{"key":"B113","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheum."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthrities","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthr Rheuma."},{"key":"B115","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fmed.2018.00063","article-title":"Role of subclinical gut inflammation in the pathogenesis of spondyloarthritis","volume":"1","author":"Rizzo","year":"2018","journal-title":"Front Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2013-203854","article-title":"Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort","volume":"73","author":"Van Praet","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.38967","article-title":"Brief report: intestinal dysbiosis in ankylosing spondylitis","volume":"67","author":"Costello","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","article-title":"Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B120","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T- cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3389\/fimmu.2018.01610","article-title":"Increased IL-22- and IL-17A-producing mucosal-associated invariant t cells in the peripheral blood of patients with ankylosing spondylitis","volume":"9","author":"Toussirot","year":"2018","journal-title":"Front Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3899\/jrheum.151133","article-title":"Involvement of mucosal-associated invariant t cells in ankylosing spondylitis","volume":"43","author":"Hayashi","year":"2016","journal-title":"J Rheumatology."},{"key":"B126","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3892\/etm.2014.2046","article-title":"T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis","volume":"21","author":"Wang","year":"2014","journal-title":"Chenggong Exp Therapeutic Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clim.2017.03.016","article-title":"IL-17 and IFN-\u03b3 producing NK and \u03b3\u03b4-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis","volume":"183","author":"Chowdhury","year":"2017","journal-title":"Clin Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17\u2013positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"54","author":"Noordenbos","year":"2011","journal-title":"Arthrt Rheum."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"N van Tok","year":"2018","journal-title":"Front Immunol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies","volume":"19","author":"Ruiz de Morales","year":"2020","journal-title":"AutoimmRev."},{"key":"B131","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.4049\/jimmunol.150.9.4168","article-title":"Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression","volume":"150","author":"Taurog","year":"1993","journal-title":"J Immunol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","article-title":"The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats","volume":"180","author":"Taurog","year":"1994","journal-title":"J Exp Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/978-1-4419-0298-6_18","article-title":"Animal models of spondyloarthritis","volume":"649","author":"Taurog","year":"2009","journal-title":"Adv Exp Med Biol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-020-00924-5","article-title":"treatment of axial spondyloarthritis: what does the future hold?","volume":"22","author":"Poddubnyy","year":"2020","journal-title":"Curr Rheumatol Rep."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"Engl J Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B139","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/Annrheumdis-2019-eular.6633","article-title":"Netakimab reduces the disease activity of radiographic axial spondyloarthritis. Results of ASTERA study","volume":"78","author":"Gaydukova","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"Van der Heijde","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14712598.2019.1554053","article-title":"Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis","volume":"19","author":"Wendling","year":"2018","journal-title":"Taylor Francis Online."},{"key":"B142","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"Van der Heijde","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial Lancet","volume":"392","author":"Van der Heijde","year":"2018"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2016","journal-title":"Lancet"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of Apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor\u2013 and interleukin-17a\u2013targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N Engl J Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature."},{"key":"B152","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet."},{"key":"B153","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.20061551","article-title":"Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia","volume":"204","author":"Michel","year":"2007","journal-title":"J Exp Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.4049\/jimmunol.0901059","article-title":"Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions","volume":"183","author":"Doisne","year":"2009","journal-title":"J Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/bjd.15358","article-title":"IL-17A localizes in the exocytic compartment of mast cells in psoriatic skin","volume":"177","author":"Brembilla","year":"2017","journal-title":"Br J Dermatol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J Immunol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic Role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/ard.2009.107649","article-title":"Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis","volume":"69","author":"Melis","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B162","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and oste-oarthritis: possible explanation for nonresponse to anti-IL-17 therapy?","volume":"16","author":"Van Baarsen","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.3390\/ijms21176401","article-title":"The Role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis","volume":"3","author":"Tsukazaki","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B164","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B165","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/art.1780360705","article-title":"Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis","volume":"36","author":"Veale","year":"1993","journal-title":"Arthr Rheum."},{"key":"B166","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/ard.2006.062042","article-title":"Ectopic lymphoid neogenesis in psoriatic arthritis","volume":"66","author":"Canete","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e115424","DOI":"10.1371\/journal.pone.0115424","article-title":"Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis","volume":"6","author":"Dolcino","year":"2014","journal-title":"PLoS ONE."},{"key":"B168","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1196\/annals.1402.013","article-title":"Synovial fluid fibroblasts and lymphocytes support the osteoclastogenesis in human psoriatic arthritis","volume":"1117","author":"Mori","year":"2007","journal-title":"Ann N Y Acad Sci."},{"key":"B169","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fimmu.2016.00057","article-title":"The role of IL-17 TH17 cells in the bone catabolic activity of PTH","volume":"7","author":"Pacifici","year":"2016","journal-title":"Front Immunol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/jid.2008.194","article-title":"Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells","volume":"129","author":"Zaba","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/jid.2014.146","article-title":"Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2013.477","article-title":"Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis","volume":"134","author":"Villanova","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat + CD3 + CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B177","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr Rheumatol Rep."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J Exp Med."},{"key":"B179","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2004.07.007","article-title":"IL-22 increases the innate immunity of tissues","volume":"21","author":"Wolk","year":"2004","journal-title":"Immunity."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur J Immunol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/art.39649","article-title":"Interleukin-9 overexpression and th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis","volume":"68","author":"Ciccia","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"12885","DOI":"10.1073\/pnas.0812530106","article-title":"IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells","volume":"106","author":"Elyaman","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B185","unstructured":"Secukinumab: a new treatment option for psoriatic arthritis529 MeaseP McInnesIB 27747580Rheumatol Ther.32016"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised,placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B187","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","article-title":"Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data","volume":"16","author":"Sakkas","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1006\/cyto.2000.0681","article-title":"Contribution of interleukin 17 to synoviummatrix destruction in rheumatoid arthritis","volume":"12","author":"Chabaud","year":"2000","journal-title":"Cytokine."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B191","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jmb.2010.07.046","article-title":"Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab","volume":"402","author":"Luo","year":"2010","journal-title":"J. Mol. Biol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/2040622318781760","article-title":"Ustekinumab in psoriatic arthritis and related phenotypes","volume":"9","author":"Dobbin-Sears","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"B193","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40744-017-0076-0","article-title":"A review of the use of secukinumab for psoriatic arthritis","volume":"4","author":"Patel","year":"2017","journal-title":"Rheumatol Ther."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3899\/jrheum.170429.C1","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a Phase III study (SPIRIT-P1)","volume":"45","author":"Van der Heijde","year":"2018","journal-title":"J Rheumatol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1136\/annrheumdis-2017-eular.1576","article-title":"SPIRIT-P2 Study GroupIxekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet."},{"key":"B197","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B198","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/PTT.S161453","article-title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis."},{"key":"B199","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","article-title":"A novel treatment for psoriatic arthritis: Janus kinase inhibitors","volume":"133","author":"Chen","year":"2020","journal-title":"Chin Med J (Engl)."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet."},{"key":"B201","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase. 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet."},{"key":"B203","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23\u2013IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.30093","article-title":"Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production","volume":"63","author":"Van Hamburg","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B206","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4049\/jimmunol.1300274","article-title":"synovial fibroblasts directly induce th17 pathogenicity via the cyclooxygenase\/prostaglandin E2 pathway, independent of IL-23","volume":"191","author":"Paulissen","year":"2013","journal-title":"J Immunology."},{"key":"B207","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jcb.22326","article-title":"IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-\u03b1 antibody: A novel mechanism of osteoclastogenesis by IL-17","volume":"108","author":"Yago","year":"2009","journal-title":"J Cell Biochem."},{"key":"B208","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cyto.2015.02.002","article-title":"The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis","volume":"74","author":"Paulissen","year":"2015","journal-title":"Citokyne."},{"key":"B209","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13075-017-1305-1","article-title":"Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis","volume":"9","author":"Penatti","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B210","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s13075-015-0800-5","article-title":"CCR6+ Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis","volume":"17","author":"Paulissen","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clim.2010.10.002","article-title":"Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis","volume":"138","author":"Zizzo","year":"2011","journal-title":"Clin Immunol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med."},{"key":"B213","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti\u2013interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B214","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B215","doi-asserted-by":"publisher","first-page":"414421","DOI":"10.3899\/jrheum.130637","article-title":"One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase ii, dose-finding, double-blind, randomized, placebo-controlled study","volume":"41","author":"Genovese","year":"2014","journal-title":"J Rheumatol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"R164","DOI":"10.1186\/ar4347","article-title":"A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis","volume":"15","author":"Martin","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B217","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A Phase II randomized study of subcutaneous ixekizumab, an anti\u2013interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"83139","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B219","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/art.40319","article-title":"Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor\u2013 and interleukin-17\u2013targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17a, in patients with rheumatoid arthritis with an inadequate response to methotrexate","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B222","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrrheum.2010.118","article-title":"Pathogenetic mechanisms in the initiation and perpetuation of Sj\u00f6gren's syndrome","volume":"6","author":"Voulgarelis","year":"2010","journal-title":"Nat Rev Rheumatol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren's syndrome","volume":"48","author":"Salomonsson","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B224","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren's syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"The Lancet."},{"key":"B225","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","article-title":"T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORa and RORg","volume":"28","author":"Yang","year":"2007","journal-title":"Immunity."},{"key":"B226","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/art.23214","article-title":"Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sj\u00f6gren's syndrome: findings in humans and mice","volume":"58","author":"Nguyen","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B227","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and local interleukin-17 and linked cytokines associated with sj\u00f6gren's syndrome immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am J Pathol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/keu004","article-title":"Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sj\u00f6gren's syndrome","volume":"53","author":"Ciccia","year":"2014","journal-title":"Rheumatology."},{"key":"B229","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1002\/art.21265","article-title":"Increased acinar damage of salivary glands of patients with Sj\u00f6gren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3\/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9\/tissue inhibitor of metalloproteinases 1 ratios","volume":"52","author":"P\u00e9rez","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B230","doi-asserted-by":"publisher","first-page":"14292","DOI":"10.1073\/pnas.1009234107","article-title":"Proinflammatory T helper type 17 cells are effective B-cell helpers","volume":"107","author":"Mitsdoerffer","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B231","doi-asserted-by":"publisher","first-page":"e0173301","DOI":"10.1371\/journal.pone.0173301","article-title":"Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS ONE."},{"key":"B232","doi-asserted-by":"publisher","first-page":"4768408","DOI":"10.1155\/2017\/4768408","article-title":"Increased interleukin-17F is associated with elevated autoantibody levels and more clinically relevant than Interleukin-17A in primary sj\u00f6gren's syndrome","volume":"2017","author":"Gan","year":"2017","journal-title":"J Immunol Res."},{"key":"B233","doi-asserted-by":"publisher","first-page":"38717","DOI":"10.1038\/srep38717","article-title":"Sexual dimorphic function of IL-17 in salivary gland dysfunction of the C57BL\/6.NOD-Aec1Aec2 model of Sj\u00f6gren's syndrome","volume":"6","author":"Voigt","year":"2016","journal-title":"Sci Rep."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/annrheumdis-2013-204584","article-title":"Th17 cells play a critical role in the development of experimental Sj\u00f6gren's syndrome","volume":"74","author":"Lin","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B235","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/annrheumdis-2012-201511","article-title":"IL-17-producing CD4\u2013CD8\u2013 T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sj\u00f6gren's syndrome","volume":"72","author":"Alunno","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B236","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","article-title":"Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation","volume":"26","author":"Laurence","year":"2007","journal-title":"Immunity."},{"key":"B237","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3389\/fimmu.2018.01755","article-title":"IL-2 inhibition of Th17 generation rather than induction of treg cells is impaired in primary sj\u00f6gren's syndrome patients","volume":"9","author":"Luo","year":"2018","journal-title":"Front Immunol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren's syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B239","doi-asserted-by":"publisher","first-page":"218467","DOI":"10.1136\/annrheumdis-2021-219882","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"2020","author":"Felten","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B240","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/tcrm.s5599","article-title":"Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis","volume":"6","author":"Koutruba","year":"2010","journal-title":"Ther Clin Risk Manag."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/ICO.0000000000000627","article-title":"dry eye signs and symptoms persist during systemic neutralization of IL-1\u03b2 by canakinumab or IL-17A by secukinumab, Cornea","volume":"34","author":"Grosskreutz","year":"2015"},{"key":"B242","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1002\/art.22665","article-title":"Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms","volume":"56","author":"Heinlen","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B243","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar4277","article-title":"Clinical associations of serum interleukin-17 in systemic lupus erythematosus","volume":"15","author":"Vincent","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B244","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clim.2008.01.019","article-title":"Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity","volume":"127","author":"Wong","year":"2008","journal-title":"Clin Immunol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crisp\u00edn","year":"2008","journal-title":"J Immunol."},{"key":"B246","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4049\/jimmunol.143.1.103","article-title":"T cell receptor alpha\/beta expressing double-negative (CD4-\/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis","volume":"143","author":"Shivakumar","year":"1989","journal-title":"Immunol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1177\/0961203312457718","article-title":"The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis Lupus","volume":"21","author":"Chen","year":"2012","journal-title":"Lupus."},{"key":"B248","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-017-1344-7","article-title":"IFN-\u03bb1 with Th17 axis cytokines and IFN-\u03b1 define different subsets in systemic lupus erythematosus (SLE)","volume":"19","author":"Oke","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B249","doi-asserted-by":"publisher","first-page":"9401432","DOI":"10.1155\/2017\/9401432","article-title":"Serum interleukin-23 in polish patients with systemic lupus erythematosus: association with lupus nephritis, obesity, and peripheral vascular disease","volume":"2017","author":"Fischer","year":"2017","journal-title":"Mediators Inflamm."},{"key":"B250","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.24499","article-title":"Th17 and natural Treg cell population dynamics in systemic lupus erythematosus","volume":"60","author":"Yang","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B251","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3899\/jrheum.170737","article-title":"Hydroxychloroquine inhibits the differentiation of th17 cells in systemic lupus erythematosus","volume":"45","author":"Yang","year":"2018","journal-title":"J Rheumatol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.637829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T12:02:21Z","timestamp":1698667341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.637829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":252,"alternative-id":["10.3389\/fimmu.2021.637829"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.637829","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"article-number":"637829"}}